全员中文属名，中山大学最新Nature论文：开创癌症动态风险适应性治疗新模式

Core Viewpoint - The article discusses a groundbreaking study on nasopharyngeal carcinoma (NPC) treatment, highlighting the transition from a "one-size-fits-all" approach to a dynamic, risk-adaptive therapy guided by circulating tumor DNA (ctDNA) monitoring, which significantly improves patient outcomes [4][21]. Group 1: Clinical Background - Nasopharyngeal carcinoma is a prevalent malignant tumor in China, particularly in Southern regions like Guangdong, with an incidence rate of 20-40 per 100,000 people per year [6]. - Traditional treatment methods have been static, applying the same regimen to all patients regardless of their individual risk profiles, which has led to over-treatment of low-risk patients and under-treatment of high-risk patients [7][10]. Group 2: Study Overview - The EP-STAR clinical trial demonstrated that ctDNA dynamic monitoring can guide risk-adaptive treatment strategies, improving survival outcomes for NPC patients [4][10]. - Patients were categorized into three risk groups based on ctDNA clearance after chemotherapy: low-risk, mid-risk, and high-risk, with tailored treatment plans for each group [10][21]. Group 3: Efficacy Results - The study reported a remarkable 3-year event-free survival rate of 89.1% for mid-risk and high-risk patients undergoing risk-adaptive therapy [12][13]. - Mid-risk patients achieved a 3-year event-free survival rate of 91.4%, while high-risk patients reached 86.5%, compared to 90.6% for low-risk patients receiving standard treatment [14]. Group 4: Biological Insights - The research team analyzed tumor samples to understand the biological basis of different risk subgroups, which provided insights into the mechanisms behind the clinical efficacy of risk-adaptive therapy [16][17]. Group 5: Safety and Economic Considerations - The risk-adaptive strategy showed good clinical tolerability with no treatment-related deaths, and while there was a slight increase in grade 3-4 adverse events, they remained manageable [18]. - Economic analysis indicated that the ctDNA-guided treatment strategy only increased costs by $2,404.1 while providing an additional 1.9 quality-adjusted life years, resulting in a cost-effectiveness ratio of $1,225.2 per quality-adjusted life year, well below the accepted threshold [18]. Group 6: Clinical Significance - This research not only offers a new treatment paradigm for NPC but also signifies a shift in cancer treatment philosophy, providing scientific evidence to optimize existing treatment guidelines [21]. - The study's findings suggest that approximately 30% of patients would require enhanced treatment under the adaptive strategy, compared to 75% under traditional guidelines [21].